For PatientsPrescribing InformationProvider Login
get-started-hero-mobile

We’re ready to support your patients and practice

We’ve made ordering and prescribing Upneeq into a simple, modernized process. Our friendly and knowledgeable customer support team is ready to help you should you need it.

Show your patients what it’s like to live with eyes wide open. Sign up to become an Upneeq provider, and help patients in your area find your practice.

Sign Up as a Provider

GET STARTED

How to bring Upneeq to your practice

For eye care professionals
1
Send patient’s prescription for Upneeq directly to RVL Pharmacy (see e-Prescribing details below).
2
Pharmacy contacts patient to review the prescription, collect payment, and answer any questions.
3
Upneeq is shipped directly to the patient’s home or preferred destination within 2-5 business days following payment.
Prescribing Directions:
Select RVL Pharmacy in your EMR.
Location: Sayreville, NJ 08872
NPI: 1770193757
NCPDP: 3157369
Fax Number: 844-567-3937
Phone Number: 844-RVL-EYES (844-785-3937)
*You can order samples of Upneeq for your practice by going to the Request Samples section below and registering.
Request Samples

Request samples

Request samples of Upneeq by registering below.

Request Samples
Location
Find a provider
Sign up today to become a Upneeq provider, and help patients in your area find your practice.
Sign Up as a Provider
Brand Resources
Brand and educational resources
Help your patients and practice learn about Upneeq by getting brand and educational resources.
Get Upneeq Resources

Contact practice support

866-600-4799orcustomercare@rvlpharma.com

Frequently asked questions

Find additional FAQsPatient PDF

  • Eye Care Professionals can prescribe Upneeq by directly contacting RVL Pharmacy.

  • Medical Aesthetics Professionals can prescribe Upneeq by signing up through our portal at this link.

  • For detailed steps scroll up to the How To section above.

  • STEP 1
    Cut open child-resistant foil pouch and remove single-use vial.

  • STEP 2
    Apply one drop to each affected eye as directed, once a day or on days when eyelids need a lift.

    • Tilt head back to apply Upneeq.

    Don’t touch the eye with the tip of the vial or touch the tip of the vial to any other surface.

    Throw the single-use vial away immediately after applying drops. Vials should not be re-used after opening.

    If wearing contact lenses, remove lenses before applying Upneeq, and wait 15 minutes before putting lenses back in.

    If more than one topical ophthalmic drug is being used, the drugs should be administered at least 15 minutes between applications.

    Upneeq should be used only as directed.
    Upneeq is designed to only be applied as an eyedrop. Each single-use vial contains enough solution for one drop in each affected eye. Keep child-resistant foil pouch sealed until ready to use. The solution should never be swallowed or ingested in any way. Store Upneeq at 68°F–77°F (20°C–25°C) and protect from excessive heat. Keep out of reach of children.

  • Eye Care Professionals:
    • When the prescription is ready, RVL Pharmacy will contact the patient directly, and the patient will be able to pay over the phone by credit card.
    • RVL Pharmacy does not accept payments from insurance providers. Upneeq is available directly to patients through a fully transparent pricing model outside of the insurance process.
  • Medical Aesthetics Professionals:
    • Patients pay directly at your practice.
  • Upneeq is available in a case of 30 individually foil-pouched single patient-use vials (NDC 73687-062-32).
  • Upneeq should be stored at 68°F to 77°F (20°C to 25°C) and should be protected from excessive heat. It should be kept out of the reach of children.

STILL HAVE QUESTIONS?

Can't find the answer you're looking for? Please get in touch with us.

Get in touch

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.


IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.


DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.


IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.


DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.

About UpneeqBefore and AfterWhat is Acquired PtosisResourcesContact Us
Prescribing Information
Privacy PolicyTerms of Use
FacebookTikTokInstagram

Distributed by: RVL Pharmaceuticals, Inc. Bridgewater, NJ 08807.©2025 RVL Pharmaceuticals, Inc. All rights reserved. PM-US-UPN-1741 03/25

Upneeq® is a registered trademark of RVL Pharmaceuticals, Inc.